AmanU.BuzdarMD

PubMed

• 6 citations
  Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
  Clinton Yam, Nour Abuhadra, Ryan Sun, Beatriz E Adrada, Qing-Qing Ding, Jason B White, Elizabeth E Ravenberg, Alyson R Clayborn, Vicente Valero, Debu Tripathy, Senthil...> ;Clinical Cancer Research. 2022 Jul 1
• Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.
  James N. Ingle, Krishna R. Kalari, Poulami Barman, Lois E. Shepherd, Matthew J. Ellis, Paul E. Goss, Aman U. Buzdar, Mark E. Robson, Junmei Cairns, Erin E. Carlson, Ab...> ;Pharmacogenetics and Genomics. 2021 Jan 1
• 11 citations
  Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
  Junmei Cairns, James N. Ingle, Tanda M. Dudenkov, Krishna R. Kalari, Erin E. Carlson, Jie Na, Aman U. Buzdar, Mark E. Robson, Matthew J. Ellis, Paul E. Goss, Lois E. S...> ;JCI Insight. 2020 Aug 20
• 9 citations
  Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
  Tanda M. Dudenkov, Duan Liu, Junmei Cairns, Sandhya Devarajan, Yongxian Zhuang, James N. Ingle, Aman U. Buzdar, Mark E. Robson, Michiaki Kubo, Anthony Batzler, Poulami...> ;Clinical Pharmacology and Therapeutics. 2019 Jul 1
• 10 citations
  Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Allian...
  Aman U. Buzdar, Vera J. Suman, Funda Meric-Bernstam, A. M. Leitch, Matthew J. Ellis, Judy C. Boughey, Gary Unzeitig, Melanie Royce, Kelly K. Hunt> ;JAMA Oncology. 2019 Jan 1
• 13 citations
  A phase II study of tipifarnib and gemcitabine in metastatic breast cancer
  Clinton Yam, Rashmi Krishna Murthy, Vicente Valero, Janio Szklaruk, Girish S. Shroff, Carol J. Stalzer, Aman U. Buzdar, James L. Murray, Wei Yang, Gabriel N. Hortobagy...> ;Investigational New Drugs. 2018 Jan 27
• 14 citations
  SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway
  Tanda M. Dudenkov, James N. Ingle, Aman U. Buzdar, Mark E. Robson, Michiaki Kubo, Irada Ibrahim-zada, Anthony Batzler, Gregory D. Jenkins, Tracy L. Pietrzak, Erin E. C...> ;Breast Cancer Research and Treatment. 2017 Apr 20
• 9 citations
  Modifying the clinical research infrastructure at a dedicated clinical trials unit: Assessment of trial development, activation, and participant accrual
  Chad Tang, Kenneth R. Hess, Dwana Sanders, Suzanne E. Davis, Aman U. Buzdar, Razelle Kurzrock, J. Jack Lee, Funda Meric-Bernstam, David S. Hong> ;Clinical Cancer Research. 2017 Mar 15
• 23 citations
  Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement.
  Chad Tang, Steven I. Sherman, Mellanie Price, Jun Weng, Suzanne E. Davis, David S. Hong, James C. Yao, Aman U. Buzdar, G. Wilding, J. Jack Lee> ;Clinical Cancer Research. 2017 Mar 15
• 41 citations
  Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial
  Robert Lesurf, Obi L. Griffith, Malachi Griffith, Jasreet Hundal, Lee Trani, Mark A. Watson, Rebecca Aft, MJ Ellis, David M. Ota, Vera J. Suman, Funda Meric-Bernstam, ...> ;Annals of Oncology. 2017 May 1
• Genomic characterisation of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy - results from the ACOSOG Z1041 (Alliance) trial.
  Lesurf, R.,Griffith, O. L.,Griffith, M.,Hundal, J.,Trani, L.,Watson, M. A.,Aft, R.,Ellis, M. J.,Ota, D.,Suman, V. J.,Meric-Bernstam, F.,Leitch, A. M.,Boughey, J. C.,Un...> ;Ann. Oncol.. 2017 Mar 23
• 403 citations
  Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
  W. Fraser Symmans, Caimiao Wei, Rebekah Gould, Xian Yu, Ya Zhang, Mei Liu, Andrew Walls, Alex Bousamra, Maheshwari Ramineni, Bruno Valentin Sinn, Kelly K. Hunt, Thomas...> ;Journal of Clinical Oncology. 2017 Jan 30
• 12 citations
  Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperati...
  Rachel A. Freedman, Drew K. Seisler, Jared C. Foster, Jeff A. Sloan, Jacqueline Lafky, Gretchen Kimmick, Arti Hurria, Harvey J. Cohen, Eric P. Winer, Clifford A. Hudis...> ;Breast Cancer Research and Treatment. 2017 Jan 1
• 40 citations
  Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prosp...
  Erica T. Warner, Karla V. Ballman, Carrie Strand, Judy C. Boughey, Aman U. Buzdar, Lisa A. Carey, William M. Sikov, Ann H. Partridge> ;Breast Cancer Research and Treatment. 2016 Jul 22
• 3 citations
  Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy
  Kathrin Strasser-Weippl, Nora Horick, Ian E. Smith, Joyce O'Shaughnessy, Bent Ejlertsen, Frances M. Boyle, Aman U. Buzdar, Pierre Fumoleau, William J. Gradishar, Migue...> ;European Journal of Cancer. 2016 Mar 1
• 31 citations
  Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole
  James N. Ingle, Krishna R. Kalari, Aman U. Buzdar, Mark E. Robson, Matthew P. Goetz, Zeruesenay Desta, Poulami Barman, Tanda T. Dudenkov, Donald Northfelt, Edith A. Pe...> ;Steroids. 2015 Jul 1
• 29 citations
  Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer
  Mitch Dowsett, Ivana Sestak, Richard Buus, Elena Lopez-Knowles, Elizabeth Mallon, Anthony Howell, John F. Forbes, Aman U. Buzdar, Jack Cuzick> ;Clinical Cancer Research. 2015 Jun 15
• 24 citations
  Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
  Kathrin Strasser-Weippl, Nora Horick, Ian E. Smith, Joyce O'Shaughnessy, Bent Ejlertsen, Frances M. Boyle, Aman U. Buzdar, Pierre Fumoleau, William J. Gradishar, Migue...> ;Breast Cancer Research. 2015 Apr 16
• 8 citations
  Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HE...
  Frances M. Boyle, Ian E. Smith, Joyce O'Shaughnessy, Bent Ejlertsen, Aman U. Buzdar, Pierre Fumoleau, William J. Gradishar, Miguel Martin, Beverly Moy, Martine Piccart...> ;European Journal of Cancer. 2015 Apr 1
• 101 citations
  Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment.
  Andrew McBride, Pamela K. Allen, Wendy A. Woodward, Michelle M. Kim, Henry Mark Kuerer, Eva Katherine Drinka, Aysegul A. Sahin, Eric A. Strom, Aman U. Buzdar, Vicente ...> ;International Journal of Radiation Oncology, Biology, Physics. 2014 Jun 1
• 152 citations
  Which threshold for ER positivity? a retrospective study based on 9639 patients
  Min Yi, Lei Huo, Kimberly B. Koenig, Elizabeth A. Mittendorf, Funda Meric-Bernstam, Henry Mark Kuerer, Isabelle Bedrosian, Aman U. Buzdar, William Fraser Symmans, Jaim...> ;Annals of Oncology. 2014 May 1
• 123 citations
  Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab ...
  Aman U. Buzdar, Vera J. Suman, Funda Meric-Bernstam, A. Marilyn Leitch, Matthew J. Ellis, Judy C. Boughey, Gary Unzeitig, Melanie Royce, Linda M. McCall, Michael S. Ew...> ;The Lancet. Oncology. 2013 Dec 1
• 2 citations
  Meta-analysis: Selective estrogen-receptor modulators reduce breast cancer incidence
  Aman U. Buzdar> ;Annals of Internal Medicine. 2013 Sep 17
• Combination endocrine treatments unproven in breast cancer
  Aman U. Buzdar> ;The Lancet. Oncology. 2013 Sep 1
• 54 citations
  Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
  Michelle M. Kim, Pamela K. Allen, A. M. Gonzalez-Angulo, W.A. Woodward, Funda Meric-Bernstam, Aman U. Buzdar, K. K. Hunt, Henry Mark Kuerer, Jennifer K. Litton, Gabrie...> ;Annals of Oncology. 2013 Aug 1
• Join now to see all

Lectures

• Medical Oncology and Hematology 2012: Clinical and Scientific Approaches that Enhance Patient Outcomes 
  The University of Texas, M. D. Anderson Cancer Center, Houston, Texas - 10/18/2012